Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight

Over 200 companies are advancing more than 240 pipeline Alzheimer's disease therapies across various clinical development stages. The market is being driven by an aging population, rising disease prevalence, and the emergence of disease-modifying therapies that enable earlier intervention and biomarker-guided care. Two therapies have recently received FDA approval: KISUNLA (donanemab) from Eli Lilly and LEQEMBI (lecanemab-irmb) from Eisai/Biogen, both targeting amyloid plaques to slow disease progression.

10/22/2026, 1:00 PM • GlobeNewswire

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share

Despite declining Eylea sales, Regeneron's strong performance is driven by Dupixent, a blockbuster drug developed with Sanofi that generated $6 billion in global sales with 38% year-over-year growth. The company's Q2 revenue grew 17% to $4.3 billion, with Dupixent collaboration revenue jumping 51%. While Dupixent faces biosimilar competition in the early 2030s, Regeneron plans to defend its market position through improved formulations, pipeline replacements, and promising candidates like olatorepatide in the weight-loss market.

10/17/2026, 3:24 PM • The Motley Fool

Matchpoint Therapeutics Expands Leadership Team with Appointment of John O’Malley, M.D., Ph.D., as Chief Medical Officer

Matchpoint Therapeutics appointed John O'Malley, M.D., Ph.D., as Chief Medical Officer to lead clinical development of its pipeline of first-in-class oral small molecules for autoimmune and inflammatory diseases. The appointment follows the company's recent $150M Series B financing. Dr. O'Malley brings extensive immunology expertise from previous roles at CRISPR Therapeutics and Sanofi.

10/14/2026, 7:00 AM • GlobeNewswire

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

The article compares Moderna and Vertex Pharmaceuticals as investment options for 2026. Moderna is expanding its mRNA platform into RSV and oncology but faces profitability challenges with a $2.8B net loss in FY2025 and 39.2% revenue decline. Vertex dominates the cystic fibrosis market with $12.1B revenue, 32.7% net margins, and $3.2B free cash flow, while diversifying into gene therapy and pain management. The author recommends Vertex for its established profitability and growing pipeline, though acknowledges Moderna's long-term platform potential.

10/13/2026, 8:17 AM • The Motley Fool

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Retension Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for hypertension and cardiovascular diseases, priced its IPO at $12 per share, raising $45 million gross proceeds. The company plans to use the funds to complete Phase 2b trials and prepare for Phase 3 trials of its lead candidate RTN-001. Trading on Nasdaq under ticker RTSN is expected to begin October 9, 2026.

10/08/2026, 9:35 PM • GlobeNewswire

Communiqué de presse : Mise en ligne du document «Q3 2026 aide-mémoire »

Sanofi announced the publication of its Q3 2026 aide-mémoire on October 6, 2026, with full quarterly results to follow on October 30, 2026. The company also announced expansions of strategic alliances with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines partnerships.

10/06/2026, 1:30 AM • GlobeNewswire

Press Release : Availability of the aide-mémoire for Q3 2026 results

Sanofi announced the availability of its Q3 2026 results aide-mémoire on October 6, 2026, with full results to be published on October 30, 2026. The company also announced expansions of strategic partnerships with Regeneron for next-generation immunology antibodies and with Cheplapharm for mature medicines.

10/06/2026, 1:30 AM • GlobeNewswire

Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider

The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

09/25/2026, 8:30 AM • GlobeNewswire

Is Regeneron Stock a Bargain Below $800?

Regeneron Pharmaceuticals' stock has declined from over $1,000 to below $800 over the past two years, primarily due to challenges with its Eylea product facing biosimilar competition. However, the company shows strong fundamentals with 17% revenue growth driven by Dupixent, successful mitigation of Eylea losses through its HD formulation, and promising pipeline candidates including the weight-loss drug olatorepatide. The analyst views the stock as attractive at current levels given its long-term growth prospects and shareholder return programs.

09/22/2026, 3:15 PM • The Motley Fool

Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase

Recludix Pharma, a clinical-stage biotech company focused on inflammatory disease treatments, announced that its CEO and head of R&D will present at the Oppenheimer Private Life Sciences Company Showcase on September 29, 2026. The company is developing STAT6 and BTK inhibitors in partnership with Sanofi, with a Phase 1 study underway for REX-8756 targeting diseases like atopic dermatitis and asthma.

09/22/2026, 8:00 AM • GlobeNewswire

Recludix Pharma to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum

Recludix Pharma, a clinical-stage biotech company developing inhibitors for inflammatory diseases, announced that its CEO and head of R&D will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. The company is conducting a Phase 1 study of REX-8756 (STAT6 inhibitor) in partnership with Sanofi and advancing a potential first-in-class BTK SH2 domain inhibitor.

09/17/2026, 8:00 AM • GlobeNewswire

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire

Immunotherapy Drugs Market 2026: Precision Medicine, Next-Generation Biologics and Expanding Cancer Indications Fuel Growth Opportunities

The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.

09/15/2026, 6:40 AM • GlobeNewswire

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

The global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.

09/15/2026, 5:58 AM • GlobeNewswire

Hummingbird Bioscience Appoints Dr. James Garner as President

Hummingbird Bioscience announced the appointment of Dr. James Garner as President. Garner brings over two decades of experience in drug development and commercialization from roles at Biogen, Takeda, and Sanofi, with a track record of overseeing 30+ product approvals. He previously served as CEO of Percheron Therapeutics and Kazia Therapeutics.

09/15/2026, 5:00 AM • GlobeNewswire